menu
    • menu

    Find Rivoceranib manufacturers, exporters & distributors on PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    1

    API Suppliers

    API Suppliers

    1

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    0

    NDC API

    NDC API

    0

    VMF

    NDC API

    0

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 0

    MARKET PLACE

    0

    API

    0

    FDF

    1INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    0

    FDF Dossiers

    FDF Dossiers

    0

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    17DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    19

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Finished Drug Prices

    NA

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 811803-05-1, Rivoceranib, Apatinib free base, Yn968d1, N-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide, N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide
    Molecular Formula
    C24H23N5O
    Molecular Weight
    397.5  g/mol
    InChI Key
    WPEWQEMJFLWMLV-UHFFFAOYSA-N
    FDA UNII
    5S371K6132
    Rivoceranib
    Rivoceranib is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Upon administration, rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
    1 2D Structure

    Rivoceranib

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide
    2.1.2 InChI
    InChI=1S/C24H23N5O/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30)
    2.1.3 InChI Key
    WPEWQEMJFLWMLV-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4
    2.2 Other Identifiers
    2.2.1 UNII
    5S371K6132
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Apatinib Mesylate

    2. Rivoceranib

    3. Rivoceranib Mesylate

    4. Yn-968d1

    5. Yn968d1

    2.3.2 Depositor-Supplied Synonyms

    1. 811803-05-1

    2. Rivoceranib

    3. Apatinib Free Base

    4. Yn968d1

    5. N-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide

    6. N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide

    7. 5s371k6132

    8. N-(4-(1-cyanocyclopentyl)phenyl)-2-(pyridin-4-ylmethylamino)nicotinamide

    9. 3-pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-

    10. Unii-5s371k6132

    11. Apatinib (in China)

    12. Rivoceranib [inn]

    13. Rivoceranib (usan/inn)

    14. Rivoceranib [usan]

    15. Rivoceranib [who-dd]

    16. Gtpl7648

    17. Schembl1814966

    18. Chembl3186534

    19. Apatinib Free Base; Yn-968d1

    20. Dtxsid601024366

    21. Amy21302

    22. Bcp02840

    23. Ex-a1794

    24. Hy-13342a

    25. Mfcd21648511

    26. Nsc772886

    27. Nsc799333

    28. S5248

    29. Zinc70466461

    30. Akos024464453

    31. Ccg-268625

    32. Db14765

    33. Ds-7455

    34. Nsc-772886

    35. Nsc-799333

    36. Sb16590

    37. N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide

    38. Ncgc00249393-01

    39. Ncgc00249393-08

    40. Ac-27461

    41. Ba175030

    42. Da-35324

    43. Cs-0003200

    44. C76598

    45. D11288

    46. Ab01274807-01

    47. Ab01274807_02

    48. Q27262801

    49. N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]nicotinamide

    50. N-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)pyridine-3-carboxamide

    2.4 Create Date
    2006-10-26
    3 Chemical and Physical Properties
    Molecular Weight 397.5 g/mol
    Molecular Formula C24H23N5O
    XLogP34.1
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count6
    Exact Mass397.19026037 g/mol
    Monoisotopic Mass397.19026037 g/mol
    Topological Polar Surface Area90.7 Ų
    Heavy Atom Count30
    Formal Charge0
    Complexity608
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Pharmacology and Biochemistry
    4.1 MeSH Pharmacological Classification

    Antineoplastic Agents

    Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

    Protein Kinase Inhibitors

    Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

    API SUPPLIERS

    read-more
    read-more

    01

    Jiangsu Hengrui Medicine

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Jiangsu Hengrui Medicine

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 37320

    Submission : 2023-01-20

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search